In this podcast, Nikolai Brun outlines why Europe’s biopharmaceutical sector is falling behind the rest of the world, and how the proposed EU pharmaceutical legislation, while containing many good ideas, may harm the sector instead. The podcast also highlights how the continuing decline in clinical trials in the EU should be setting off alarm bells in Brussels, even if the reaction of many bureaucrats implies that they don’t see this neither as a concern nor a priority.

Listen to it now!